{"entity":{"id":"hs-20089","kind":"drug","name":"HS-20089","aka":[],"tldr":"HS-20089 is an experimental antibody-drug conjugate from Hansoh BioMedical R&D in phase 3 trials for ovarian cancer and endometrial cancer, with its target not yet stated publicly.","summary":"HS-20089 is an antibody-drug conjugate developed by Hansoh BioMedical R&D. The sponsor describes its target as B7-H4, which OnCo does not yet have a target page for. The sponsor states: HS-20089 is a humanised IgG1 anti-B7-H4 monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a protease-cleavable linker (average drug-to-antibody ratio of about 6), delivering the payload to B7-H4-expressing tumour cells, given intravenously every three weeks in ovarian and endometrial cancer. ClinicalTrials.gov describes the intervention as: All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatmen. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06855069 (HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer), in ovarian cancer and endometrial cancer. The largest, NCT06855069, plans to enrol 468 participants with primary completion expected 2027-03-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of HS-20089","url":"https://clinicaltrials.gov/search?intr=HS-20089"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","endometrial"],"sections":[],"technologies":[],"targets":["b7h4"],"drugs":[],"companies":["hansoh-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06855069","nct06014190"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","mechanism":"HS-20089 is a humanised IgG1 anti-B7-H4 monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a protease-cleavable linker (average drug-to-antibody ratio of about 6), delivering the payload to B7-H4-expressing tumour cells, given intravenously every three weeks in ovarian and endometrial cancer.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hs-20089/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"b7h4","kind":"target","name":"B7-H4 (VTCN1)","route":"/targets/b7h4/"}],"company":[{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/"}],"trial":[{"id":"nct06855069","kind":"trial","name":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","route":"/trials/nct06855069/"},{"id":"nct06014190","kind":"trial","name":"HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer","route":"/trials/nct06014190/"}]}}